# reload+after+2024-01-21 21:44:19.111938
address1§200 Connell Drive
address2§Suite 1500
city§Berkeley Heights
state§NJ
zip§07922
country§United States
phone§908 517 7330
fax§866 271 3466
website§https://www.cyclacel.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Spiro George Rombotis', 'age': 64, 'title': 'President, CEO & Executive Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 763551, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul  McBarron', 'age': 62, 'title': 'Executive VP of Finance, CFO, COO, Secretary & Executive Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 394675, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark H. Kirschbaum M.D.', 'age': 62, 'title': 'Senior VP & Chief Medical Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 523843, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Gill  Christie', 'age': 66, 'title': 'Director of Human Resources', 'yearBorn': 1957, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
dividendRate§0.6
dividendYield§0.0377
exDividendDate§1697673600
fiveYearAvgDividendYield§8.54
beta§0.655
priceToSalesTrailing12Months§77.72075
currency§USD
dateShortInterest§1702598400
exchange§NCM
quoteType§EQUITY
shortName§Cyclacel Pharmaceuticals, Inc. 
longName§Cyclacel Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1133361000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§30e2be38-8d7d-375a-841a-72cfbb0be0a4
gmtOffSetMilliseconds§-18000000
recommendationKey§none
quickRatio§1.04
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
